R2PLx-22

General Information


DRACP ID  DRACP00840

Peptide Name   R2PLx-22

Sequence  GIMDTVKNAAKNLAGQLLDKLK 

Sequence Length  23

UniProt ID  Not available

PubChem CID  Not available

Origin  skin secretions of the pickerel frog (Rana palustris)

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
NCI-H157 Lung squamous cell carcinoma Carcinoma IC50=843.40 μM MTT assay 24h 1
MDA-MB-435S Amelanotic melanoma Carcinoma IC50=872.70 μM MTT assay 24h 1
PC-3 Prostate carcinoma Carcinoma IC50=283.90 μM MTT assay 24h 1
U-251MG Astrocytoma Carcinoma IC50=104.10 μM MTT assay 24h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=109.30 μM MTT assay 24h 1

Hemolytic Activity  Horse erythrocytes: Low haemolytic activity

Normal (non-cancerous) Cytotoxicity  HMEC-1: IC50=588.20 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  Mix



Physicochemical Information


Formula  C102H179N29O30S

Absent amino acids  CEFHPRSWY

Common amino acids  KL

Mass  271641

Pl  10.33

Basic residues  4

Acidic residues  2

Hydrophobic residues  9

Net charge  2

Boman Index  -2273

Hydrophobicity  -14.78

Aliphatic Index  110.43

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30279210

Title  A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells

Doi 10.1042/BSR20180710

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.